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Abstract  
Diabetic peripheral neuropathy (DPN) is a common disabling complication of diabetes.  
Almost half of DPN patients develop neuropathic pain for which current analgesic treatments 
are inadequate. Understanding the role of genetic variability in the development of painful 
DPN is needed for improved understanding of pain pathogenesis, for better patient 
stratification in clinical trials and to target therapy more appropriately. Here we examined the 
relationship between variants in the voltage gated sodium channel Nav1.7 and neuropathic 
pain in a deeply phenotyped cohort of patients with DPN. While no rare variants were found 
in 78 participants with painless DPN, we identified twelve rare Nav1.7 variants in ten (out of 
111) study participants with painful DPN. Five of these variants had previously been 
described in the context of other neuropathic pain disorders and seven have not previously 
been linked to neuropathic pain. Those patients with rare variants reported more severe pain 
and greater sensitivity to pressure stimuli on quantitative sensory testing. 
Electrophysiological characterization of two of the novel variants (M1852T and T1596I) 
demonstrated gain of function changes as a consequence of markedly impaired channel fast 
inactivation. By using a structural model of Nav1.7 we were also able provide further insight 
into the structural mechanisms underlying fast activation and the role of the C-terminal 
domain in this process. Our observations suggest that rare Nav1.7 variants contribute to the 
development neuropathic pain in patients with diabetic peripheral neuropathy. Their 
identification should aid understanding of sensory phenotype, patient stratification and help 
target treatments effectively. 
 














Diabetes mellitus is a common chronic disease that affects 415 million people worldwide 
(IDF Diabetic Atlas) and the numbers are expected to rise arriving to 642 million by 2040. 
Diabetic peripheral neuropathy (DPN) is one of the most frequent long-term complications of 
diabetes affecting 30-50% of patients and is associated with significant morbidity [26; 59]. 
Up to 50 % of the patients suffering from DPN will develop neuropathic pain which is 
typically expressed as spontaneous pain but, in a minority, also includes evoked pain such as 
brush evoked allodynia [2; 9; 62] . Painful DPN can have a major deleterious impact on the 
patients` quality of life and, unfortunately, the current first line analgesics show modest 
efficacy and poor tolerability [28]. In order to develop new and better target existing 
therapies for painful DPN we need to improve our understanding of neuropathic pain 
pathophysiology and its individual variability in DPN.  
Risk factors for the development of painful DPN include older age, poor glycaemic control 
and more severe neuropathy. However, genetic factors have been relatively under-explored 
[32]. Here investigate the relationship between variants in the voltage gated sodium channel 
Nav1.7 and painful DPN.  
The rationale for studying Nav1.7 is that this voltage gated sodium channel is expressed in 
nociceptors and amplifies subthreshold stimuli. It is therefore a key determinant of nociceptor 
excitability and selective blockers of Nav1.7 are under active development as novel 
analgesics (for review see [21]). Nav1.7 has been shown to be important in pathological pains 
states in humans [6; 64]. Homozygous loss of function mutations in Nav1.7 have been shown 
to cause congenital insensitivity to pain [16]. Conversely, heterozygous gain of function 
variants have been associated with a number of pain disorders including: inherited 
erythromelalgia (IEM) [67], paroxysmal extreme pain disorder (PEPD) [27] and idiopathic 
small fibre neuropathy [25]. In addition to these rare disorders associated with high impact 
variants, single nucleotide polymorphisms in Nav1.7 may have a more subtle effect in 
modulating the risk and severity of pain in acquired pain disorders. An example is the gain of 
function R1150W variant in Nav1.7 which was associated with an increased pain score in 
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Painful DPN is one of the most common acquired neuropathic pain states in which a 
metabolic insult interacts with genotype; whether Nav1.7 variants are associated with 
neuropathic pain in DPN has not been established. We have therefore investigated whether 
common or rare Nav1.7 variants are associated with neuropathic pain in a cohort of patients 
with DPN that have undergone detailed sensory phenotyping. Detailed sensory phenotyping 
enables patient stratification in a manner that will reflect the pathomechanisms and that may 
be predictive of treatment response [4; 19]. Our aims were therefore to determine if Nav1.7 
variants were related to neuropathic pain, to determine the functional effects of such Nav1.7 
variants and if Nav1.7 variants could be related to somatosensory phenotype in order to 
improve patient stratification. 
 
Materials and Methods 
Study participants and Clinical phenotyping  
Study participants were recruited as part of the Pain in Neuropathy Study (PiNS) [61]. PiNS 
is an observational cross-sectional multicentre study approved by the National Research 
Ethics Service of the UK (No.: 10/H0706/35). All study participants signed written consent 
before enrolment. A detailed description of the study can be found elsewhere [61] and will 
only briefly be described. Participants underwent a structured neurological examination, 
nerve conduction studies, skin biopsy for intra-epidermal nerve fibre assessment (IENFD) 
and a detailed quantitative sensory testing (QST) assessment. Further drug, laboratory, and 
clinical investigation data were retrieved from the clinical medical records. The data included 
nerve conduction study data and the most recent routine haematological and biochemical 
parameters, including HbA1c. Basic clinical parameters, such as weight, height, and blood 
pressures, were measured for each participant. Only study participants that had diabetes 
mellitus with evidence of clinical length dependant neuropathy [59] confirmed by 
abnormalities on either nerve conduction studies or IENFD would proceed to sequencing of 
their DNA (Figure S1, available online as supplemental digital content at 
http://links.lww.com/PAIN/A509).   
A comprehensive structured upper and lower limb neurological examination was performed 
to detect clinical signs of a peripheral neuropathy [37; 43]. The examination included 
assessment of temperature, light touch and pinprick sensation, joint position proprioception, 
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findings were quantified with the Toronto Clinical Scoring System (TCSS) [10] and MRC 
sensory sum score.  
Nerve conduction tests were performed with an ADVANCE system (Neurometrix, 
Massachusetts, USA) and used conventional reusable electrodes. Sural sensory and peroneal 
motor nerve conduction studies were performed [11]. Our protocol was in line with those 
recommended by the American Academy of Neurology and American Association of 
Electrodiagnostic Medicine [22].  
The determination of IENFD from skin biopsy samples is a validated and sensitive diagnostic 
tool for the assessment of small fibre neuropathies, including diabetic neuropathy [38]. 
Biopsy samples were taken in accordance with the consensus document produced by the 
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the 
utilisation of skin biopsy samples in the diagnosis of peripheral neuropathies [38].  
QST to determine somatosensory phenotypes was performed according to a previously 
published protocol of the German research network of neuropathic pain (DFNS) [50]. QST is 
a measure of sensory perception to a given stimulus. This test can show abnormalities in 
sensory function. QST data were entered into the data analysis system, Equista, provided by 
the DFNS. Equista transformed the raw QST data into z-scores thus normalising for age, sex, 
and the body location of testing [41; 51]. A z-score of zero is equal to the mean of the 
population. A score of greater or less than two standard deviations from the mean indicates 
gain of function or loss of function, respectively.  
Orthostatic hypotension, as a marker of autonomic neuropathy, was assessed by measuring 
lying and standing blood pressure in accordance with established protocols [1]. Orthostatic 
hypotension was defined as either a 20 mm Hg reduction in systolic or a 10 mm Hg reduction 
in diastolic blood pressure. Survey of Autonomic Symptoms [70] is an instrument that 
measures the presence and impact of autonomic symptoms. It consists of 12 questions that 
are individually rated on a 6-point rating scale from 0 (not at all) to 5 (a lot).  
 
Definition of neuropathic pain 
Only study participants with a confirmed diabetic peripheral neuropathy proceeded to 
neuropathic pain (NeuP) subtyping (Figure S1, available online as supplemental digital 
content at http://links.lww.com/PAIN/A509). The presence of chronic NeuP caused by 
peripheral DPN was determined at the time of the clinical assessment and was in line with the 
IASP definition of neuropathic pain i.e. ‘pain caused by a lesion or disease of the 
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neuropathic pain [29]. Thus participants were divided in to those with NeuP (painful DPN) 
and those without NeuP (painless DPN). Only study participants with chronic NeuP present 
for at least three months were included in the NeuP group. Study participants with non-NeuP 
in the extremities, such as musculoskeletal pain of the ankle, were included in the non-NeuP 
group.  
The assessment of each study participant therefore satisfied the following criteria: 
1. Pain with a distinct neuroanatomically plausible distribution i.e. pain symmetrically 
distributed in the extremities – completion of body map and clinical history. 
2. A history suggestive of a relevant lesion or disease affecting the peripheral or central 
somatosensory system – diagnosis of diabetes mellitus and a history of neuropathy symptoms 
including decreased sensation, positive sensory symptoms e.g. burning, aching pain mainly in 
the toes, feet or legs. 
3. Demonstration of distinct neuroanatomically plausible distribution of neuropathic pain– 
presence of clinical signs of peripheral neuropathy i.e. decreased distal sensation or 
decreased/absent ankle reflexes. 
4. Demonstration of the relevant lesion or disease by at least one confirmatory test – 
abnormality on either the nerve conduction tests or IENFD. 
 
Pain severity was calculated either from a pain intensity diary or the average pain over the 
last 24 hours. The pain intensity diary was completed over seven days, with participants 
recording pain at 9 am and 9 pm daily on an 11 point scale, with 0 being no pain and 10 the 
worst pain imaginable. The severity of NeuP from the pain diary was calculated as the mean 
of the pain scores obtained from the seven day pain intensity diary. Further quantification of 
the NeuP was calculated with the Douleur Neuropathique en 4 Questions (DN4) [7]. The 
DN4 is a screening tool for neuropathic pain with a score greater than four highly suggestive 
of neuropathic pain. Study participants completed a body map that highlighted the 
distribution of any pain experienced. Brief Pain Inventory (BPI) pain interference and pain 
severity subscales [58]  were used to assess any type of pain (non-neuropathic and 
neuropathic) that study participants experienced and the impact of the pain on activities of 
daily living. BPI pain relief quantifies the relief of pain, as a percentage, that participants 
enjoyed after administration of an analgesic.  Neuropathic Pain Symptom Inventory (NPSI) 
[8]), a self-administered questionnaire, evaluated neuropathic pain symptoms including 
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Sequencing of Nav1.7 
Sequencing of the coding regions of SCN9A was undertaken by next generation sequencing 
using the HaloPlex Target Enrichment System (Agilent Technologies, Santa Clara, CA, 
USA) and MiSeq Sequencing Platform (Illumina, Inc., San Diego, CA, USA). Sequence 
analysis was performed via an in-house bioinformatics pipeline utilising Burrows-Wheeler 
Alignment tool (BWA) [39] for mapping to the human genome and Platypus [48] for variant 
calling.Variants were annotated against reference sequences NM_002977.3 (mRNA) and 
NP_002968.1 (protein). Any variant that was both present at >1% allele frequency in the 
Exome Variant Database (http://evs.gs.washington.edu/EVS) and not previously reported in 
the literature in association with painful neuropathy was considered unlikely to be pathogenic 
and was not investigated further. Variants of potential interest were confirmed by Sanger 
sequencing by capillary electrophoresis using a 3730 DNA Analyzer (Applied Biosystems, 
Foster City, CA, USA) 
 
Plasmids and site-directed mutagenesis.  
Human Nav1.7 cDNA was cloned into a modified pcDNA3 expression vector containing 
downstream IRES and dsRED2 sequences (SCN9A-IRES-DsRED) (Cox 2006). Human β1 
and β2 subunits were cloned into pIRES2-AcGFP (SCN1B-IRES-SCN2B-IRES-eGFP) [16]. 
Mutations were introduced using QuikChange II XL site-directed mutagenesis kit (Agilent). 
HEK293T cell culture and transfection.  
Human embryonic kidney HEK-293T cells were grown in a Dulbecco’s modified Eagle’s 
culture medium (DMEM/F-12, Invitrogen) containing 10% fetal bovine serum and 
maintained under standard conditions at 37 °C in a humidified atmosphere containing 5% 
CO2. Cells were transfected using the jetPEI™ transfection reagent (Polyplus-transfection 
Inc.) with either WT or mutant Nav1.7 channel combined with β1 and β2 subunits (2:1 ratio). 
Cells were used 36 to 72 hours after transfection. 
Electrophysiology.  
Whole-cell patch clamp recordings were conducted at room temperature using an Axopatch 
200B Amplifier, the Digidata 1550B Low Noise Data Acquisition System and the 
pClamp10.6 software (Molecular Devices). Data were filtered at 5kHz and digitized at 
20kHz. Capacity transients were cancelled and series resistance compensated at 70-90% in all 
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extracellular solutions contained (in mM): 140 NaCl,3 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 
pH 7.3 with NaOH (adjusted to 320 mOsm/L with glucose). Patch pipettes were filled with 
an internal solution containing (in mM) 140 CsF, 10 NaCl, 1  EGTA, 10 HEPES, pH 7.3 with 
CsOH (adjusted to 310 mOsm/L with glucose) and had a typical resistance of 2-3MΩ. Leak 
currents were subtracted using a P/5 protocol, applied after the test pulse. A holding potential 
of -100mV and an intersweep interval of 10s was used for all the protocols. Current voltage 
curves (I-V curves) were fitted using a combined Boltzmann and linear ohmic relationship: 
I/Imax=Gmax (Vm-Erev)/(1+exp(V1/2-Vm)/k). Normalized conductance-voltage curves (activation 
curves) were fitted with a Boltzmann equation G/Gmax=1/(1+exp(V1/2-Vm)/K) were G was 
calculated as follows G=I/(Vm-Erev). Similarly, the steady-state fast inactivation curves were 
fitted with I/Imax=1/(1+exp-( V1/2-Vm)/k) and the steady-state slow inactivation with 
I/Imax=Rin+(1-Rin)/(1+exp-( V1/2-Vm)/k). In all the equations V1/2 represents the half-activation 
and respectively half inactivation potential, Vm is the membrane potential, Erev the reversal 
potential, k the slope factor, G the conductance and I the current at a given Vm; Gmax and Imax 
are the maximum conductance and current respectively; Rin is the fraction of channels that 
are resistant to slow inactivation.  
Structural modeling  
The sequences of human NaV channels were aligned to the known structures of the 
cockroach Nav homologue NavPaS [54] and the Nav1.5 C-terminal domain [63] using the 
structural alignment tool EXPRESSO [3; 20; 44-46]. 
The alignment was manually edited and prepared for input into modeller (version 9.18) [42; 
53; 65] by matching the sequence of the structured templates exactly, and removing the 
sequences of insertions. Residues 1–34, 421–722 (1–2 inter-subunit linker), 974–1168 (2–3 
inter-subunit linker) were deleted and replaced by a chain break. Both available structures 
were used to template the model building. Calmodulin and FGF13 from the C-terminal 
structure were included. We generated 100 candidate models and assessed them with 
modellers inbuilt DOPE (M.-y. Shen and Sali 2006 [55]) score. Promising models were 
manually inspected and were found to show minimal variation. 
Statistical Analysis.  
SPSS Statistics Version 22 (IBM) and GraphPad Prism were used for statistical analysis. The 
QST z-scores were compared across the three groups with one-way ANOVA (LSD post hoc 
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normality with the D’Agostino-Pearson normality test and by visual inspection of their 
distribution. All other data were not normally distributed and reported as median with 
interquartile range (IQR). Data were compared between two groups with Mann-Whitney U 
test. Categorical data was analysed with χ2 squared test of association. Significance was set at 




Study participants selection  
The Pain in Neuropathy Study has recently been described in detail [61]. This study includes 
a cohort of 191 study participants with definite DPN i.e. diabetes mellitus with evidence of 
clinical length dependant neuropathy confirmed by abnormalities on either nerve conduction 
studies or IENFD (Figure S1, available online as supplemental digital content at 
http://links.lww.com/PAIN/A509). In 189 of these participants DNA was available for 
analysis (and these are the study participants described here). The 189 study participants with 
definite DPN were separated into two groups: (i) the painful DPN group comprised of 111 
participants with neuropathic pain (NeuP) (ii) the painless DPN group comprised of 78 
participants without NeuP. The painful DPN group all satisfied the definition of definite 
neuropathic as defined by the NeuPSIG/IASP grading system [29]. 
As previously described there were no significant differences between the two groups in 
terms of age, gender, BMI, blood pressure, type 2 diabetes prevalence, and time since 
diabetes mellitus diagnosis (Table S1, available online as supplemental digital content at 
http://links.lww.com/PAIN/A508). The participants with painful DPN suffered from a more 
severe DPN and had poorer diabetic control than the study participants with painless DPN 
(Table S1, available online as supplemental digital content at 
http://links.lww.com/PAIN/A508).  
Identification of Nav1.7 variants 
In both groups we then screened for rare Nav1.7 variants i.e. missense variants present at less 
than 1% frequency in population databases (Exome Variant Database and/or Exome 
Aggregation Consortium) and variants previously reported in the literature to be associated 
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111 study participants from the painful DPN group revealed the presence of 12 rare Nav1.7 
variants in 10 study participants (Figure 1 and Table 1). Five of these variants were 
previously described in the literature as being associated with pain disorders and having a 
gain of function effect on Nav1.7: V991L/M932L (note that these variants are in complete 
linkage disequilibrium [25]); W1538R [17], R185H [31], and I739V [30]. A further variant 
L1267V [35] has been reported in a patient with painful neuropathy. However, it was stated 
that this variant did not confer hyperexcitability on DRG neurons and this patient had an 
additional SCN11A variant (and so pathogenicity is uncertain). The other six variants (I564T, 
K655R, S802G, K1043N, T1596I, M1852T) have never been described before in association 
with neuropathic pain (Table 1 and Figure 1). Most of the identified variants were only found 
in single study participants with the exception of R185H which was found in two study 
participants (Table 1). Also, there was one patient that carried four Nav1.7 rare variants 
V991L, M932L, W1538R and K1043T. Interestingly and in contrast to the painful DPN 
group, no rare Nav1.7 variants were found in the 78 study participants with painless DPN. 
We also screened for more common Nav1.7 variants (i.e. nonsynonymous substitution that 
have a frequency in population databases higher than 1%), including R1150W which was 
associated with an increased pain score in a previous study [47]. No statistically significant 
difference between the two groups could be noticed for these polymorphisms (Table S2, 
available online as supplemental digital content at http://links.lww.com/PAIN/A508).  
Clinical description of the study participants carrying Nav1.7 rare variants  
We compared the clinical characteristics of the 10 study participants carrying the Nav1.7 rare 
variants to the rest of the 101 study participants from the painful DPN group without the 
Nav1.7 rare variants.  
The age, gender proportion, BMI, diabetic control (HbA1c), blood pressure, and type 2 
diabetes prevalence were similar between the two groups (Table 2). The TCSS and MRC 
sensory sum score were also not significantly different indicating that the severity of the 
neuropathy does not differ. However, the study participants carrying rare Nav1.7 variants had 
been diagnosed for a significantly shorter duration. Also, for six of the study participants 
carrying rare Nav1.7 variants, the onset of neuropathic pain was at a similar time as the 
diagnosis of diabetes (Table 1).  None of the study participants carrying a rare variant 
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The study participants suffering from painful DPN completed a set of questionnaires that 
quantified the severity of neuropathic pain, the frequency and intensity of symptoms 
associated with neuropathic pain, impact on quality of life and the frequency and impact of 
autonomic symptoms. The study participants carrying rare Nav1.7 variants reported higher 
scores across all questionnaires for pain intensity and the difference reached a statistical 
significant value for the superficial spontaneous pain portion of the Neuropathic Pain 
Symptom Inventory (Table 2). Therefore, the study participants carrying rare variants 
reported more severe burning pain than the remaining study participants with painful DPN. 
There were no differences regarding the other parameters.  
In order to better assess the sensory phenotype and to have more insight into 
pathophysiological mechanisms we also performed QST (Quantitative Sensory Testing) of 
the feet using the protocol developed by the DFNS [49]. Although most of the QST 
parameters were similar between the two groups, the z-score for pressure pain thresholds was 
significantly higher for the study participants with the rare Nav1.7 variants (Figure S2, 
available online as supplemental digital content at http://links.lww.com/PAIN/A509). In 
addition, the z-score for pressure pain thresholds was significantly higher for the study participants 
carrying rare Nav1.7 variants when compared to the study participants with painless DPN (Figure S2, 
http://links.lww.com/PAIN/A509). Study participants carrying rare Nav1.7 variants were 
therefore more sensitive to deep pressure and reported pain at lower pressures when applied 
to the arch of the foot.   
Selection of Nav1.7 variants for functional characterization 
Among all the six Nav1.7 variants not previously described in the literature, two were 
selected for further functional characterization: M1852T and T1596I. The selection was 
based on the following criteria: (i) position in important functional domains (ii) alteration of 
highly conserved residues (iii) important amino acid exchange (high Grantham distance) (iv) 
predicted as pathogenic by four different prediction algorithms (Align GVGD 
(http://agvgd.hci.utah.edu/), SIFT (http://sift.jcvi.org), MutationTaster 
(www.mutationtaster.org) and Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/)).  
The M1852T substitution changes a methionine with a polar amino acid to threonine. M1852 
is situated in the C-terminal part of the protein and is highly conserved in every member of 
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1 A and B). The variant was not present in the EVS database and was present at a very low 
frequency (%MAF 0.0016) in the ExAC database.  
The T1596I substitution introduces an isoleucine, a hydrophobic amino acid, in place of a 
threonine. This amino acid sits at the top of the fourth helix of domain IV of the channel, an 
important helix for the voltage dependency of the channel and is highly evolutionary 
conserved and also conserved in all the different Nav human isoforms (Figure 1 A and C).  
The T1596I is present at a very low frequency in EVS and ExAC databases (%MAF 0.03 and 
0.01, respectively).  
Prediction programs like Align GVGD, SIFT MutationTaster, and PolyPhen-2 classified both 
M1852T and T1596I as “C65, likely to interfere with function”, “deleterious”, “disease 
causing” and “probably damaging”, respectively.   
Functional analysis of M1852T and T1596I variants  
To investigate the effect that the M1852T and T1596I variants may have on the biophysical 
properties of the channel, we introduced these mutations into the cDNA of human Nav1.7 
and expressed the mutated channels in HEK293T cells. Representative whole-cell voltage 
clamp currents from transfected cells are shown in Figure 2A. The mutations had no 
significant effect on the voltage dependence of activation of the channel (Figure 2B and D) 
but drastically changed the steady-state fast inactivation (Figure 2C).  A 14 mV depolarizing 
shift of the half-inactivation potential (V1/2) could be seen for the M1852T channels and a 
15mV positive shift for the T1596I channels. In addition, the mutant channels exhibited a 
significant increase in the slope factor for fast inactivation, the change being more prominent 
for the M1852T (9.1± 0.3 compared with 7.6 ± 0.3 for the T1596I and 5.6 ± 0.2 for the WT). 
The positive shift of the steady-state fast inactivation curve as well as the change in the slope 
factor led to a marked increase in the overlap between the activation and the fast inactivation 
(Figure 2D). This overlap predicts a larger window current for both M1852T and T1596I 
compared with the WT signifying that a substantially larger fraction of channels would be 
active at a given resting membrane potential. No significant effect on the steady-state slow 
activation was found (Figure 2 E).  
To further characterise the effects of the M1852T and T1596I variants on the inactivation 
properties of Nav1.7 sodium channels we analysed the open state fast inactivation kinetics. 
Single exponential fits of sodium current decay demonstrated that fast inactivation occurred 
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type currents inactivated with a τ = 1.7 ± 0.1 ms while M1852T and T1596I currents 
inactivated with a significantly increased τ (3.4 ± 0.3 ms, p<0.0001 and 2.9 ± 0.5 ms, p<0.05 
respectively compared with the WT). We also investigated the kinetics of the recovery from 
fast inactivation. Sodium channels containing the T1596I mutation recovered 3.6 times more 
quickly than WT channels (τ =28.7 ± 6.8 compared to τ =102.3 ± 16.7 for the WT, p<0.005) 
while no significant change was found for the M1852T channels (Figure 2 G). 
One of the ways that Nav1.7 channels are thought to contribute to neuronal excitability is by 
generating slow depolarizations that boost subthreshold stimuli [18]. We therefore decided to 
examine inward currents produced by slow ramp depolarizations (Figure 2H). An increase in 
the ramp current could be observed for both of the mutants, the M1852T mutation having a 
stronger effect.  
Structural insights from the M1852T and T1596I variants  
To gain further insights into the effect of these two variants we constructed a structural model 
of the human Nav1.7 channel. The model was based on the recently published structure of the 
eukaryotic Nav homolog NavPS [54] and the structure of the human Nav1.5 C-terminal 
domain [63]. Interestingly, this model shows that the C-terminal M1852T variant is located 
directly beneath and in contact with the linker between domains III and IV (Figure 3 A and 
B). Fast inactivation of VGSCs is thought to occur via movement of this ‘III-IV linker’. The 
position of this variant at this interface between the C-terminal domain and the α-helical part 
of the III-IV linker is therefore entirely consistent with its functional effects. Intriguingly, a 
recent structure of the Nav1.4 channel also now reveals that this interaction is state-dependent 
and does not occur in the open state [66].  It is therefore tempting to speculate that 
interactions at this interface stabilise the inactivated state and are reduced by the M1852T 
variant. Eitherway, this result now highlights how a dynamic interaction between these two 
parts of the channel is important for the control of fast inactivation. 
The other variant, T1596I is located at the top of the positively-charged S4 helix within the 
voltage sensor of domain IV at the interface with the pore helices of domain 1 (Figures 3A 
and C).  The voltage sensor of domain IV is also known to be an important determinant of 
fast inactivation: its movement being a rate limiting step for both development and recovery 
from fast inactivation [13]. The location of this variant is therefore also consistent with its 
functional effects and highlights the important role that this dynamic interface plays in the 









The development of painful DPN is a complex multifactorial process that involves an 
interaction between the metabolic disturbances characteristic of diabetes mellitus, 
environmental factors and genotype. In this study we address the question of whether 
individual genetic variations in the Nav1.7 could have an impact on the development of 
painful DPN. We screened for Nav1.7 variants in a cohort of 189 study participants 
comprised of 111 with painful DPN and 78 with a painless DPN phenotype. While no rare 
variants could be identified in the painless group, we found a significant number (12) of rare 
Nav1.7 variants in ten participants from the painful DPN group. Functional characterization 
of two of these variants (M1852T and T1596I) demonstrated gain of function changes, 
consistent with an increase in neuronal excitability. This is the first study that has 
investigated the presence of Nav1.7 rare variants in patients with painful DPN using a cohort 
in which detailed phenotyping was used in order to stratify patients according to sensory 
profile [29]. The establishment of somatosensory phenotype allowed us to examine the 
differences between the ten study participants carrying Nav1.7 rare variants and the rest of 
the painful DPN group. Three statistical significant differences were found: (1) the study 
participants carrying rare Nav1.7 variants had been diagnosed for a significantly shorter 
duration (2) they reported more severe burning pain and (3) they were more sensitive to deep 
pressure and reported pain at lower pressures when applied to the arch of the foot. The 
absence of a clearer phenotypic distinction between the two groups is similar to a study in 
which erythromelalgia patients carrying the pathogenic Nav1.7 mutation I848T could not be 
phenotypically distinguished from those not carrying the mutation[69]. The addition of supra-
threshold QST paradigms might improve our ability to differentiate mechanistically relevant 
subgroups [33]. Larger replication studies will be needed to determine if these phenotypic 
aspects could be used in the future to stratify patients for potential genetic testing. This could 
be relevant to future treatment choices given the major effort to develop selective small 
molecule blockers of Nav1.7, some of which are currently in clinical trials [68].  
Among the twelve rare Nav1.7 variants identified five were already shown to be associated 
with painful related disorders: R185H, I739V, V991L, M932L and W1538R. The first four 
(R185H, I739V, V991L/M932L) were previously found in patients with idiopathic small 
fibre neuropathy [31]. The latter (W1538R) was identified in a patient with primary 
erythromelalgia [17]. One previous study also reported an association between the variants 
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population controls [40]. In contrast to Li et al., we used painless DPN as a control group 
rather than normal controls without diabetes as this is the most appropriate comparison in 
order to address the question as to which variants promote the development of neuropathic 
pain in DPN. It has been hypothesised that because Nav1.7 is expressed in pancreatic β cells 
variants in this ion channel could confer vulnerability to injury [34].  
The comparison of the published clinical phenotypes of previously reported patients with 
Nav1.7 variants with those  from our cohort carrying the same variants revealed some 
differences For instance, the I739V variant was described in patients with small fibre 
neuropathy and severe autonomic dysfunction [30]. However, in our study we did not elicit 
significant autonomic dysfunction from the affected study participant. The R185H variant 
was also previously found in patients with small fibre neuropathy but who had minimal 
autonomic dysfunction [31]. In our cohort this variant was found in two patients one of which 
had a postural drop in blood pressure (suggesting sympathetic autonomic dysfunction)  and 
one that didn`t. The patient from our study carrying the W1538R variant (described 
previously in a patient with primary erythromelalgia [17]), did not demonstrate 
erythromelalgia nor changes in symptomology related to changes in temperature. These 
findings suggest that one variant can produce different clinical pain phenotypes which will 
depend on environmental context. For instance in DPN the structural injury to autonomic 
axons as a consequence of diabetes will have a major impact on autonomic function 
independent of any direct effects of Nav1.7 variants on autonomic neuron excitability [31].  
In our cohort none of the participants reported a family history, and only one participant 
reported symptoms that began before a diagnosis of diabetes was made. We therefore propose 
that these rare variants in Nav1.7 may act as risk factors promoting the development of 
neuropathic pain in the context of an environmental trigger (diabetes) rather than causing a 
Mendelian pain disorder.  
Six of the twelve rare Nav1.7 variants identified by this study (I564T, K655R, S802G, 
K1043N, T1596I, M1852T) are new variants, not having been described in the literature in 
association with pain related disorders. However, one of them, K655R was reported in 
patients with febrile seizures [56]. In our case, the study participant carrying the K655R did 
not report a history of seizures.  
An analysis of the unpublished variants using different pathogenic predictive algorithms 
pinpointed two of them (T1596I and M1852T) as highly likely to be pathogenic. Their 





Copyright © 2017 The Author(s) Published by Wolters Kluwer Health Inc on behalf of the International Association for the Study of Pain.
15 
 
properties of the channel. Both T1596I and M1852T exhibited a strong shift (14-15mV) of 
the steady-state fast inactivation curve towards more depolarised membrane potentials, 
increased window current, slower inactivation kinetics and, for the T1596I variant, a 
significant faster recovery from inactivation. All these changes are consistent with a gain of 
function of the channel which would most likely lead to an increase in neuronal excitability 
thus contributing to pain signalling.  
Our structural model reveals that the position of these mutations is consistent with their 
functional effects. Many previous structural models of Nav1.7 have relied upon comparison 
to the prokaryotic Nav channels.  However, we have been able to take advantage of the recent 
high-resolution cryoEM structure of a eukaryotic homologue, NavPS [54] to construct an 
almost complete model of human Nav1.7. In this model, M1852T is located in the fifth alpha 
helix of the C terminal domain, just below the III-IV linker, indicating possible interactions 
between this residue and the linker. As the III-IV linker is known to be a critical structural 
determinant of fast inactivation, the position of this variant not only a structural basis of our 
electrophysiological findings, but also highlights the dynamic role that this interface between 
the C terminal domain and the III-IV linker may play in fast inactivation. Likewise, the 
position of the T1596I variant highlights an important functional role for the interface 
between the voltage sensor of domain IV and the pore forming helices of domain I.  
Interestingly, mutation of a conserved glutamine situated at the top of S6 (Q270K) in domain 
I of Nav1.5 also impairs the fast inactivation [12], This glutamine is predicted to be in close 
proximity to T1596 and therefore suggests an important and highly-conserved role for this 
dynamic interface in the regulation of fast inactivation. 
Compared with the other Nav1.7 variants previously associated with painful neuropathies 
(such as small fibre neuropathy), T1596I and M1852T appear unique. Most of the described 
variants in idiopathic small fibre neuropathy have relatively mild effects on fast inactivation 
[25]. On the other hand, Nav1.7 mutations associated with PEPD, a severe pain condition 
characterised by episodic pain and flare response of the sacrum, peri-ocular and mandibular 
regions [14; 23; 27; 36; 57; 60] have much more profound effects on inactivation (V1298F, 
V1299F, I1461T, G1607R, L1612P, M1627K, A1632E). Two of these mutations G1607R, 
L1612P are also located in S4 of domain IV with the others in the S4-S5 linker of domain III 
(V1298F, V1299F), S4-S5 linker of domain IV (M1627K, A1632E) or part of the IFM motif 
in linker III-IV (I1461T). However, the M1852T variant we describe here is the first mutation 
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also provide evidence for a possible state-dependence of the interaction of the III-IV linker 
with the C-terminal domain during inactivation. 
Although broad generalisations can be drawn when comparing the biophysical impact of 
Nav1.7 variants with clinical phenotype (for instance that IEM is associated with enhanced 
channel activation and PEPD with impaired channel inactivation) we still have an incomplete 
understanding of how channel dysfunction causes specific pain phenotypes. Certain Nav1.7 
variants have also been shown to cause the degeneration of DRG axons in vitro particularly 
under conditions of metabolic stress [24; 52] and so an interesting topic for future studies will 
be whether Nav1.7 variants may not only impact on pain phenotype in DPN but also 
neuropathy progression.    
In conclusion, this study reveals an important link between painful DPN and Nav1.7 
suggesting that rare Nav1.7 variants may predispose patients with diabetic neuropathy to 
developing neuropathic pain. Despite the challenges prospective studies of diabetes and its 
complications would be very helpful in extending these findings. Better understanding of 
genetic variability in neuropathic pain disorders combined with improved sensory 
phenotyping should also improve patient stratification for future clinical trials and help target 
therapy more appropriately. 
 
Acknowledgements 
We would like to thank all patients and healthy volunteers for their participation.  
DHLB is a Wellcome Senior Clinical Scientist (202747/Z/16/Z). DLHB and SJT are 
members of the Wellcome Trust funded OXION Initiative (WT084655MA). This work was 
supported by the Wellcome Trust through a Strategic Award to the London Pain Consortium 
(ref. no. 083259). DHLB, IB and AT are members of the DOLORisk consortium funded by 
the European Commission Horizon 2020 (ID633491). DHLB and AT are members of the 
International Diabetic Neuropathy Consortium, the Novo Nordisk Foundation, grant number 
NNF14SA0006. ACT is an Honorary Research Fellow of the Brain Function Research 
Group, School of Physiology, Faculty of Health Science, University of the Witwatersrand. 
JJC is funded by the MRC (G1100340) and the Wellcome Trust (200183/Z/15/Z). 
 





Copyright © 2017 The Author(s) Published by Wolters Kluwer Health Inc on behalf of the International Association for the Study of Pain.
17 
 
ASCR undertakes consultancy and advisory board work for Imperial College Consultants- in 
the last 36 months this has include remunerated work for: Spinifex, Abide, Astellas, 
Neusentis, Merck, Mitsubishi, Aquilas, Asahi Kasei, Galapagos, Toray, Quartet, Relmada, 
Novartis and Orion.  ASCR was the owner of share options in Spinifex Pharmaceuticals from 
which personal benefit accrued upon the acquisition of Spinifex by Novartis in July 2015 and 
from which future milestone payments may occur. 
 ASCR is named as an inventor on patents: Rice A.S.C., Vandevoorde S. and Lambert D.M 
Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain. WO 
2005/079771; Okuse K. et al Methods of treating pain by inhibition of vgf activity 
EP13702262.0/ WO2013 110945. DLB has undertaken consultancy and advisory board work 
for Oxford innovation- in the last 36 months this has included renumerated work for: Abide, 
Biogen, GSK, Lilly, Mitsubishi Tanabe, Mundipharma, TEVA and Pfizer. 
All other authors declare no conflict of interest. 
Supplemental digital content 
Supplemental tables are available online as supplemental digital content at 
http://links.lww.com/PAIN/A508; supplemental figures at available online as supplemental 
digital content at http://links.lww.com/PAIN/A509. 
Supplemental video content 
Supplemental video content is available at http://links.lww.com/PAIN/A510 
 
References 
[1] Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and 
multiple system atrophy. The Consensus Committee of the American Autonomic Society and 
the American Academy of Neurology. Neurology 1996;46(5):1470-1470. 
[2] Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful 
diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes 
Care 2011;34(10):2220-2224. 
[3] Armougom F, Moretti S, Poirot O, Audic S, Dumas P, Schaeli B, Keduas V, Notredame C. Expresso: 
automatic incorporation of structural information in multiple sequence alignments using 3D-
Coffee. Nucleic Acids Res 2006;34(Web Server issue):W604-608. 
[4] Baron R, Forster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-
related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol 
2012;11(11):999-1005. 
[5] Baron R, Maier C, Attal N, Binder A, Bouhassira D, Cruccu G, Finnerup NB, Haanpaa M, Hansson P, 





Conflict of interest 
Copyright © 2017 The Author(s) Published by Wolters Kluwer Health Inc on behalf of the International Association for the Study of Pain.
18 
 
Segerdahl M, Serra J, Sindrup S, Sommer C, Tolle T, Vollert J, Treede RD. Peripheral 
neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain 
2017;158(2):261-272. 
[6] Bennett DL, Woods CG. Painful and painless channelopathies. Lancet Neurol 2014;13(6):587-599. 
[7] Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, 
Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, 
Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and 
development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114(1-
2):29-36. 
[8] Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-
Minet M, Collin E, Grisart J, Boureau F. Development and validation of the Neuropathic Pain 
Symptom Inventory. Pain 2004;108(3):248-257. 
[9] Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in 
diabetic patients: a French cross-sectional study. PLoS One 2013;8(9):e74195. 
[10] Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. 
Diabetes Care 2002;25(11):2048-2052. 
[11] Buschbacher R, Orahlow N. Manual of nerve conduction studies. New York, New York: Demos 
Medical Publishing, 2006. 
[12] Calloe K, Schmitt N, Grubb S, Pfeiffer R, David JP, Kanter R, Cordeiro JM, Antzelevitch C. Multiple 
arrhythmic syndromes in a newborn, owing to a novel mutation in SCN5A. Can J Physiol 
Pharmacol 2011;89(10):723-736. 
[13] Capes DL, Goldschen-Ohm MP, Arcisio-Miranda M, Bezanilla F, Chanda B. Domain IV voltage-
sensor movement is both sufficient and rate limiting for fast inactivation in sodium channels. 
J Gen Physiol 2013;142(2):101-112. 
[14] Choi JS, Boralevi F, Brissaud O, Sanchez-Martin J, Te Morsche RH, Dib-Hajj SD, Drenth JP, 
Waxman SG. Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons. 
Nat Rev Neurol 2011;7(1):51-55. 
[15] Choi JS, Cheng X, Foster E, Leffler A, Tyrrell L, Te Morsche RH, Eastman EM, Jansen HJ, Huehne 
K, Nau C, Dib-Hajj SD, Drenth JP, Waxman SG. Alternative splicing may contribute to time-
dependent manifestation of inherited erythromelalgia. Brain 2010;133(Pt 6):1823-1835. 
[16] Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, 
Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, 
Gribble FM, Woods CG. An SCN9A channelopathy causes congenital inability to experience 
pain. Nature 2006;444(7121):894-898. 
[17] Cregg R, Laguda B, Werdehausen R, Cox JJ, Linley JE, Ramirez JD, Bodi I, Markiewicz M, Howell 
KJ, Chen YC, Agnew K, Houlden H, Lunn MP, Bennett DL, Wood JN, Kinali M. Novel mutations 
mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical 
manifestations of primary erythromelalgia. Neuromolecular Med 2013;15(2):265-278. 
[18] Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism 
underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci 
1998;18(23):9607-9619. 
[19] Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH. The 
effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a 
randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 
2014;155(11):2263-2273. 
[20] Di Tommaso P, Moretti S, Xenarios I, Orobitg M, Montanyola A, Chang JM, Taly JF, Notredame C. 
T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences 
using structural information and homology extension. Nucleic Acids Res 2011;39(Web Server 
issue):W13-17. 
[21] Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na(V)1.7 sodium channel: from molecule to man. 





Copyright © 2017 The Author(s) Published by Wolters Kluwer Health Inc on behalf of the International Association for the Study of Pain.
19 
 
[22] England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher MA, 
Howard JF, Kinsella LJ, Latov N, Lewis RA, Low PA, Sumner AJ. Distal symmetric 
polyneuropathy: a definition for clinical research: report of the American Academy of 
Neurology, the American Association of Electrodiagnostic Medicine, and the American 
Academy of Physical Medicine and Rehabilitation. Neurology 2005;64(2):199-207. 
[23] Estacion M, Dib-Hajj SD, Benke PJ, Te Morsche RH, Eastman EM, Macala LJ, Drenth JP, Waxman 
SG. NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological 
changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations 
and produces symptoms of both disorders. J Neurosci 2008;28(43):11079-11088. 
[24] Estacion M, Vohra BP, Liu S, Hoeijmakers J, Faber CG, Merkies IS, Lauria G, Black JA, Waxman 
SG. Ca2+ toxicity due to reverse Na+/Ca2+ exchange contributes to degeneration of neurites 
of DRG neurons induced by a neuropathy-associated Nav1.7 mutation. J Neurophysiol 
2015;114(3):1554-1564. 
[25] Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, Choi JS, Estacion M, Lauria G, Vanhoutte EK, 
Gerrits MM, Dib-Hajj S, Drenth JP, Waxman SG, Merkies IS. Gain of function Nanu1.7 
mutations in idiopathic small fiber neuropathy. Ann Neurol 2012;71(1):26-39. 
[26] Feldman EL, Nave KA, Jensen TS, Bennett DL. New Horizons in Diabetic Neuropathy: 
Mechanisms, Bioenergetics, and Pain. Neuron 2017;93(6):1296-1313. 
[27] Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, Klugbauer 
N, Wood JN, Gardiner RM, Rees M. SCN9A mutations in paroxysmal extreme pain disorder: 
allelic variants underlie distinct channel defects and phenotypes. Neuron 2006;52(5):767-
774. 
[28] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, 
Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, 
Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a 
systematic review and meta-analysis. Lancet Neurol 2015;14(2):162-173. 
[29] Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, Cruccu G, 
Freeman R, Hansson P, Nurmikko T, Raja SN, Rice AS, Serra J, Smith BH, Treede RD, Jensen 
TS. Neuropathic pain: an updated grading system for research and clinical practice. Pain 
2016;157(8):1599-1606. 
[30] Han C, Hoeijmakers JG, Ahn HS, Zhao P, Shah P, Lauria G, Gerrits MM, te Morsche RH, Dib-Hajj 
SD, Drenth JP, Faber CG, Merkies IS, Waxman SG. Nav1.7-related small fiber neuropathy: 
impaired slow-inactivation and DRG neuron hyperexcitability. Neurology 2012;78(21):1635-
1643. 
[31] Han C, Hoeijmakers JG, Liu S, Gerrits MM, te Morsche RH, Lauria G, Dib-Hajj SD, Drenth JP, Faber 
CG, Merkies IS, Waxman SG. Functional profiles of SCN9A variants in dorsal root ganglion 
neurons and superior cervical ganglion neurons correlate with autonomic symptoms in small 
fibre neuropathy. Brain 2012;135(Pt 9):2613-2628. 
[32] Hebert HL, Veluchamy A, Torrance N, Smith BH. Risk factors for neuropathic pain in diabetes 
mellitus. Pain 2017;158(4):560-568. 
[33] Helas T, Sagafos D, Kleggetveit IP, Quiding H, Jonsson B, Segerdahl M, Zhang Z, Salter H, Schmelz 
M, Jorum E. Pain thresholds, supra-threshold pain and lidocaine sensitivity in patients with 
erythromelalgia, including the I848Tmutation in NaV 1.7. Eur J Pain 2017;21(8):1316-1325. 
[34] Hoeijmakers JG, Faber CG, Merkies IS, Waxman SG. Channelopathies, painful neuropathy, and 
diabetes: which way does the causal arrow point? Trends Mol Med 2014;20(10):544-550. 
[35] Huang J, Han C, Estacion M, Vasylyev D, Hoeijmakers JG, Gerrits MM, Tyrrell L, Lauria G, Faber 
CG, Dib-Hajj SD, Merkies IS, Waxman SG, Group PS. Gain-of-function mutations in sodium 
channel Na(v)1.9 in painful neuropathy. Brain 2014;137(Pt 6):1627-1642. 
[36] Jarecki BW, Sheets PL, Jackson JO, 2nd, Cummins TR. Paroxysmal extreme pain disorder 
mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast 





Copyright © 2017 The Author(s) Published by Wolters Kluwer Health Inc on behalf of the International Association for the Study of Pain.
20 
 
[37] Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver agreement in the assessment of 
muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 
1991;14(11):1103-1109. 
[38] Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, Nolano M, Merkies ISJ, 
Polydefkis M, Smith AG, Sommer C, Valls-Solé J. European Federation of Neurological 
Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of 
small fiber neuropathy. Report of a joint task force of the European Federation of 
Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2010;17(7):79-92. 
[39] Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. 
Bioinformatics 2009;25(14):1754-1760. 
[40] Li QS, Cheng P, Favis R, Wickenden A, Romano G, Wang H. SCN9A Variants May be Implicated in 
Neuropathic Pain Associated With Diabetic Peripheral Neuropathy and Pain Severity. Clin J 
Pain 2015;31(11):976-982. 
[41] Magerl W, Krumova EK, Baron R, Tölle T, Treede R-D, Maier C. Reference data for quantitative 
sensory testing (QST): refined stratification for age and a novel method for statistical 
comparison of group data. Pain 2010;151(3):598-605. 
[42] Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A. Comparative protein structure 
modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000;29:291-325. 
[43] Medical Research Council - Nerve Injuries Research Committee. Aids to the examination of the 
peripheral nervous system: Saunders Elsevier on behalf of Guarantors of Brain, 2010. 
[44] Notredame C, Higgins DG, Heringa J. T-Coffee: A novel method for fast and accurate multiple 
sequence alignment. J Mol Biol 2000;302(1):205-217. 
[45] O'Sullivan O, Suhre K, Abergel C, Higgins DG, Notredame C. 3DCoffee: combining protein 
sequences and structures within multiple sequence alignments. J Mol Biol 2004;340(2):385-
395. 
[46] Poirot O, Suhre K, Abergel C, O'Toole E, Notredame C. 3DCoffee@igs: a web server for 
combining sequences and structures into a multiple sequence alignment. Nucleic Acids Res 
2004;32(Web Server issue):W37-40. 
[47] Reimann F, Cox JJ, Belfer I, Diatchenko L, Zaykin DV, McHale DP, Drenth JP, Dai F, Wheeler J, 
Sanders F, Wood L, Wu TX, Karppinen J, Nikolajsen L, Mannikko M, Max MB, Kiselycznyk C, 
Poddar M, Te Morsche RH, Smith S, Gibson D, Kelempisioti A, Maixner W, Gribble FM, 
Woods CG. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl 
Acad Sci U S A 2010;107(11):5148-5153. 
[48] Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SRF, Consortium WGS, Wilkie AOM, McVean G, 
Lunter G. Integrating mapping-, assembly- and haplotype-based approaches for calling 
variants in clinical sequencing applications. Nat Genet 2014;46(8):912-918. 
[49] Rolke R, Baron R, Maier C, Tolle TR, Treede RD, Beyer A, Binder A, Birbaumer N, Birklein F, 
Botefur IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihofner C, 
Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory 
testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol 
and reference values. Pain 2006;123(3):231-243. 
[50] Rolke R, Baron R, Maier C, Tölle TR, Treede RDD, Beyer A, Binder A, Birbaumer N, Birklein F, 
Bötefür IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihöfner C, 
Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory 
testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol 
and reference values. Pain 2006;123(3):231-243. 
[51] Rolke R, Magerl W, Campbell K, Schalber C, Caspari S, Birklein F, Treede R. Quantitative sensory 
testing: a comprehensive protocol for clinical trials. Eur J Pain 2006;10(1):77-88. 
[52] Rolyan H, Liu S, Hoeijmakers JG, Faber CG, Merkies IS, Lauria G, Black JA, Waxman SG. A painful 





Copyright © 2017 The Author(s) Published by Wolters Kluwer Health Inc on behalf of the International Association for the Study of Pain.
21 
 
diameter axons associated with intracellular Ca2+ dysregulation and decrease in ATP levels. 
Mol Pain 2016;12. 
[53] Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 
1993;234(3):779-815. 
[54] Shen H, Zhou Q, Pan X, Li Z, Wu J, Yan N. Structure of a eukaryotic voltage-gated sodium channel 
at near-atomic resolution. Science 2017;355(6328). 
[55] Shen MY, Sali A. Statistical potential for assessment and prediction of protein structures. Protein 
Sci 2006;15(11):2507-2524. 
[56] Singh NA, Pappas C, Dahle EJ, Claes LR, Pruess TH, De Jonghe P, Thompson J, Dixon M, Gurnett 
C, Peiffer A, White HS, Filloux F, Leppert MF. A role of SCN9A in human epilepsies, as a cause 
of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet 
2009;5(9):e1000649. 
[57] Suter MR, Bhuiyan ZA, Laedermann CJ, Kuntzer T, Schaller M, Stauffacher MW, Roulet E, Abriel 
H, Decosterd I, Wider C. p.L1612P, a novel voltage-gated sodium channel Nav1.7 mutation 
inducing a cold sensitive paroxysmal extreme pain disorder. Anesthesiology 
2015;122(2):414-423. 
[58] Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic 
nonmalignant pain. J Pain 2004;5(2):133-137. 
[59] Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone 
V, Vinik A, Bernardi L, Valensi P, Group TDNE, Albers JW, Amarenco G, Anderson H, Arezzo J, 
Backonja MM, Biessels GJ, Bril V, Cameron N, Cotter M, England J, Feldman E, Frontoni S, 
Hilsted J, Low P, Malik RA, O'Brien PC, Pop-Busui R, Perkins B, Rayman G, Russell J, Sindrup S, 
Smith G, Stevens M, Várkonyi T, Veves A, Vileikyte L, Ziegler D, Zochodne D, Jones T. Diabetic 
neuropathies: update on definitions, diagnostic criteria, estimation of severity, and 
treatments. Diabetes Care 2010;33(10):2285-2293. 
[60] Theile JW, Jarecki BW, Piekarz AD, Cummins TR. Nav1.7 mutations associated with paroxysmal 
extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated 
resurgent sodium currents. J Physiol 2011;589(Pt 3):597-608. 
[61] Themistocleous AC, Ramirez JD, Shillo PR, Lees JG, Selvarajah D, Orengo C, Tesfaye S, Rice AS, 
Bennett DL. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study 
determining the somatosensory phenotype of painful and painless diabetic neuropathy. Pain 
2016;157(5):1132-1145. 
[62] Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, Mathieu C, Colin IM. 
Prevalence and impact on quality of life of peripheral neuropathy with or without 
neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. 
Diabetes Metab 2009;35(3):206-213. 
[63] Wang C, Chung BC, Yan H, Lee SY, Pitt GS. Crystal structure of the ternary complex of a NaV C-
terminal domain, a fibroblast growth factor homologous factor, and calmodulin. Structure 
2012;20(7):1167-1176. 
[64] Waxman SG, Merkies IS, Gerrits MM, Dib-Hajj SD, Lauria G, Cox JJ, Wood JN, Woods CG, Drenth 
JP, Faber CG. Sodium channel genes in pain-related disorders: phenotype-genotype 
associations and recommendations for clinical use. Lancet Neurol 2014;13(11):1152-1160. 
[65] Webb B, Sali A. Comparative Protein Structure Modeling Using MODELLER. Curr Protoc 
Bioinformatics 2014;47:5 6 1-32. 
[66] Yan Z, Zhou Q, Wang L, Wu J, Zhao Y, Huang G, Peng W, Shen H, Lei J, Yan N. Structure of the 
Nav1.4-beta1 Complex from Electric Eel. Cell 2017. 
[67] Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, Fan J, Bu D, Liu B, Fan Z, Wu G, Jin J, Ding B, Zhu X, Shen Y. 
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary 
erythermalgia. J Med Genet 2004;41(3):171-174. 
[68] Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, 





Copyright © 2017 The Author(s) Published by Wolters Kluwer Health Inc on behalf of the International Association for the Study of Pain.
22 
 
a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-
blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol 
2017;16(4):291-300. 
[69] Zhang Z, Schmelz M, Segerdahl M, Quiding H, Centerholt C, Juréus A, Carr TH, Whiteley J, Salter 
H, Kvernebo MS, Ørstavik K, Helås T, Kleggetveit I-P, Lunden LK, Jørum E. Exonic mutations in 
SCN9A (NaV1.7) are found in a minority of patients with erythromelalgia. Scandinavian 
Journal of Pain 2014;5(4):217-225. 
[70] Zilliox L, Peltier AC, Wren PA, Anderson A, Smith AG, Singleton JR, Feldman EL, Alexander NB, 
Russell JW. Assessing autonomic dysfunction in early diabetic neuropathy: The Survey of 
Autonomic Symptoms. Neurology 2011;76(12):1099-1105. 
 
Figure legends  
Figure 1 – Nav1.7 variants identified in study participants with painful diabetic 
peripheral neuropathy 
A. Schematic of Nav1.7 channel topology. The variants previously reported in the literature 
as associated with painful neuropathy are represented with blue dots and the newly 
identified variants with red ones.   
B. Sequence alignment of human Nav1.1-Nav1.9 channels and of Nav1.7 channel in different 
species showing the conserved M1852 amino acid in red.  
C. Sequence alignment of human Nav1.1-Nav1.9 channels and of Nav1.7 channel in different 
species showing the conserved T1596 amino acid in red.  
 
Figure 2 – Effect of M1852T and T1596I variants on the biophysical properties of 
Nav1.7 channels  
A. Representative currents elicited from a holding potential of -100 mV to different test pulse 
potentials (50ms) ranging from -80 to 40mV in 5mV increments, for the WT (black), 
M1852T (red) or T1596 (blue) channels.  
B. Normalized peak current-voltage relationship curves from traces in panel A for the WT 
(black dots, V1/2 = -29.9 ± 1.3, k = 5.7 ± 0.3, n=19), M1852T (red squares, V1/2 = -27.6 ± 1.3, 
k = 6.3 ± 0.5, n=11) or T1596 (blue triangles, V1/2 = -26.6 ± 2.4, k = 5.5 ± 0.6, n=9) channels. 
C.  Steady-state fast inactivation curves for the WT (black dots, V1/2 = -86.6 ± 1.4, k = 5.6 ± 
0.2, n=18), M1852T (red squares, V1/2 = 72.5 ± 3, k = 9.1± 0.3, n=11, P ≤ 0.0001) or T1596 
(blue triangles, V1/2 = 71.2 ± 2.2, k = 7.6 ± 0.3, n=9, P ≤ 0.0001) channels. Currents were 
elicited with test pulses to -10 mV following 500 ms inactivating prepulses. 
D. Overlapping voltage dependence of steady-state activation and steady-state fast 
inactivation. The inset shows an enlargement of the overlapping area representing the 
window current for the WT(black), M1852T(red) and T1596I(blue) channels.    
E.  Steady-state slow inactivation curves for the WT (black dots, V1/2 = -61.1 ± 2.8, k = 13.7 
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triangles, V1/2 = -60.9 ± 2.4, k = 11.7± 0.7, n=9) channels. Currents were elicited with test 
pulses to -10 mV following 30s inactivating prepulses and a pulse to -120mV to remove fast 
inactivation. 
F. Open-state fast-inactivation kinetics for the WT (black dots, n=19), M1852T (red squares, 
n=11) or T1596 (blue triangles, n=9) channels, measured by fitting the current decay of the 
traces in A with a single exponential function.  
G. Recovery from inactivation for the WT (black dots, τ =102.3 ± 16.7, n=14), M1852T (red 
squares, τ =106.3 ± 21.8, n=9) or T1596 (blue triangles, τ =28.7 ± 6.8, n=8) channels 
measured using two -10 mV test pulses lasting 20 ms applied from a holding potential of -100 
mV and separated by increasing durations 
H. Mean ramp currents for the WT (black, n=11), M1852T (red, n=7) or T1596 (blue, n=8) 
channels. The currents were evoked by depolarizing the membrane potential at a rate of 
0.2mV/ms from -100 to 0 mV. The response has been rescaled as the percentage of the 
maximal peak inward current obtained from traces in panel A. 
Data information: In (B–G), data are presented as mean ± SEM. Statistical analysis were 
performed using one-way ANOVA combined with Dunnett post hoc analysis for multiple 
comparisons. p values given compared with the WT. V1/2 represents the half-activation and 
respectively half inactivation potential, k the slope factor, 
Figure 3 – Nav1.7 channel structural model   
A. Side view of the Nav1.7 structural model showing the M1852 (magenta) and T1596 
(yellow). 
B.  Enlargement of the region containing the M1852 residue; note the proximity to the III-IV 
linker  
C. Enlargement of the region containing T1596; note the proximity to the S6 of domain I   
The transmembrane domains D I, D II, D III, D IV are represented in dark blue, light blue, 
cyan and aquamarine respectively.  The cytoplasmic linker III-IV (L III-IV) is in dark red and 
the C-terminal domain (CTD) in cream.  
 
Table legends  
Table 1. Clinical description of the study participants with painful diabetic neuropathy 
carrying Nav1.7 rare variants 
The 24 hour pain score was the average pain intensity over the preceding 24 hours rated on a 
11-point Likert scale with 0 rated as “no pain” and 10 rated as “worst pain imaginable”. The 
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neuropathic pain. Postural blood pressure drop was used as a measure of autonomic 
dysfunction. Almost all participants were prescribed analgesics that included at least one drug 
recommended for the treatment of neuropathic pain. The BPI pain severity quantified the 
severity of pain and the BPI pain relief was quantified the analgesic effect enjoyed by the 
study participants.  
   
MAF = minor allele frequency, ExAC= Exome Aggregation Consortium 
 
Table 2.  Summary of variables that were compared between the study participants 
with Nav1.7 rare variants and the rest of the painful diabetic peripheral neuropathy 
group 
Data shown as median (interquartile range) and analysed by Mann-Whitney U Test. 
Categorical data were analysed by Fischer’s exact test, and values and percentages are 
shown. 
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Table 1. Clinical description of the study participants with painful diabetic neuropathy carrying Nav1.7 rare variants 
 
The 24 hour pain score was the average pain intensity over the preceding 24 hours rated on a 11-point Likert scale with 0 rated as “no pain” and 10 rated as 
“worst pain imaginable”. The DN4 score is a screening toll for neuropathic pain with a score greater than four suggestive of neuropathic pain. Postural 
blood pressure drop was used as a measure of autonomic dysfunction. Almost all participants were prescribed analgesics that included at least one drug 
recommended for the treatment of neuropathic pain. The BPI pain severity quantified the severity of pain and the BPI pain relief was quantified the 
analgesic effect enjoyed by the study participants.  
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 Painful diabetic neuropathy   
With rare Nav1.7 variants                  Without 
rare Nav1.7 variant 
Number 10 101 
Male  7 (70 %) 70 (69.3 %) 
Age (years) 61 (49.5-69.8) 67.6 (57.7-73.) 
HbA1c (%) 8.4 (7.6-9.5) 7.5 (6.8-8.9) 
Type 2 diabetes 9 (90%) 90 (89.1%) 
Duration of diabetes 
(years) 
9.5 (3.2-12.8) 14.7 (8.5-22.7) * 
BMI (kg/m
2
) 30.7 (28.5-36.7) 30.5 (26.4-36.1) 










2 (20%) 25 (26.9%) 
      
MRC sensory sum 
score 
10.5 (5-12.8) 6 (3-12) 
TCSS Total (adjusted) 11 (9.5-13.3) 11 (8-13.5) 
TCSS Symptoms score 
(adjusted) 
3 (2-4) 3(2-4) 
TCSS Sensory 
examination 
4 (3-5) 3 (2-5) 
TCSS Examination 8.5 (7-9.3) 8 (5-10.5) 
      
IENFD (fibres/mm) 0.6 (0-1.4) 0.9 (0.3-1.6) 
      
Pain over last 24 
hours 
7 (5.5-8.3) 5.5 (4-8) 
Seven day pain diary  6.5 (4.9-7.2) 5 (2.9-6.8) 
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BPI Pain Interference 5.8 (7.9-2.8) 4.1 (2.5-6.1) 
BPI Pain Severity 5.4 (3.8-7.1) 4.5 (2.5-6.3) 
BPI Pain relief (%) 50 (30-100) 40 (0-60)  
      
NPSI Total 5.2 (2.7-5.7) 3 (1.6-4.6) 
NPSI Deep 
Spontaneous Pain 
3 (0-4.5) 1 (0-4) 
NPSI Superficial 
Spontaneous Pain 
7 (5-8.5) 4 (0-7) * 
NPSI Evoked 
Spontaneous Pain 
3 (1.2-4.9) 1.7 (0-4.3) 
NPSI Paraesthesiae 8 (3.5-8) 4.3 (1.9-8) 
NPSI Paroxysmal Pain 4.5 (3.3-6.3) 3.5 (0.4-6.1) 
      
Autonomic symptom 
score 
5 (1.5-7) 4 (3-6) 
Autonomic impact 
score 




Table 2.  Summary of variables that were compared between the study participants with Nav1.7 rare 
variants and the rest of the painful diabetic peripheral neuropathy group 
 
Data shown as median (interquartile range) and analysed by Mann-Whitney U Test. Categorical data 
were analysed by Fischer’s exact test, and values and percentages are shown. 










I II III IV
Nav1.1 M D A L R I Q M E E R F M A S N
Nav1.2 M D A L R I Q M E E R F M A S N
Nav1.3 M D A L R I Q M E D R F M A S N
Nav1.4 M D A L K Q T M E E K F M A A N
Nav1.5 M D A L K I Q M E E K F M A A N
Nav1.6 L D I L R Q Q M E E R F V A S N
Nav1.7 M D S L R S Q M E E R F M S A N
Nav1.8 L D S L K A N M E E K F M A T N
Nav1.9 L D S M K A MM E E K F M E A N
Nav1.1 Y F V S P T L F R V I R L A R I
Nav1.2 Y F V S P T L F R V I R L A R I
Nav1.3 Y F V S P T L F R V I R L A R I
Nav1.4 Y F V S P T L F R V I R L A R I
Nav1.5 Y F F S P T L F R V I R L A R I
Nav1.6 Y F V S P T L F R V I R L A R I
Nav1.7 Y F V S P T L F R V I R L A R I
Nav1.8 S Y F S P T L F R V I R L A R I












Human M D S L R S QM E E R F M S A N
Macaca M D S L R S QM E E R F M S A N
Bos M D S L R S QM E E R F M S A N
Canis M D S L R S QM E E R F M S A N
Rat M D S L R S QM E E R F M S A N
Mouse M D S L R S QM E E R F M S A N
Monodelphis M D T L R L QM E E R F V A A N
Human Y F V S P T L F R V I R L A R I
Macaca Y F V S P T L F R V I R L A R I
Bos Y F V S P T L F R V I R L A R I
Canis Y F V S P T L F R V I R L A R I
Rat Y F V S P T L F R V I R L A R I
Mouse Y F V S P T L F R V I R L A R I
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